Payment overview · 2025
General Payments
$171.00
4 reported records · 4 companies
Healthcare provider profile · identity verified
Julia Vu, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, GA · NPI 1013303932
Verified facts
What the public records show
CMS Open Payments records show Julia Vu, MD received $171.00 in general payments during 2025 across 4 reported records.
Gilead Sciences, Inc. accounted for 68.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vemlidy.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vemlidy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $116.76 | 68.3% | 1 | 2025 |
| RedHill Biopharma Inc. | Unresolved — no canonical attribution shown | $18.85 | 11.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.36 | 10.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.03 | 10.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $171.00 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $116.76 | 1 | 2025 |
Source payment records
|
|||||
| Talicia Normalized: talicia |
Drug | RedHill Biopharma Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 276 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 212 |
| Metformin Hcl | Metformin Hcl | 397 | 172 |
| Omeprazole | Omeprazole | 306 | 167 |
| Losartan Potassium | Losartan Potassium | 258 | 127 |
| Diclofenac Sodium | Diclofenac Sodium | 255 | 139 |
| Montelukast Sodium | Montelukast Sodium | 237 | 153 |
| Alendronate Sodium | Alendronate Sodium | 224 | 114 |
| Fenofibrate | Fenofibrate | 203 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 96 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 184 | 115 |
| Lisinopril | Lisinopril | 182 | 82 |
| Gabapentin | Gabapentin | 177 | 97 |
| Simvastatin | Simvastatin | 167 | 71 |
| Naproxen | Naproxen | 147 | 95 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 134 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 97 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 126 | 103 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 118 | 118 |
| Glipizide Er | Glipizide | 113 | 58 |
| Famotidine | Famotidine | 107 | 76 |
| Meloxicam | Meloxicam | 103 | 68 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 42 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 88 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 35 |
| Donepezil Hcl | Donepezil Hcl | 79 | 36 |
| Finasteride | Finasteride | 76 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 71 | 27 |
| Prednisone | Prednisone | 68 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 36 |
| Allopurinol | Allopurinol | 63 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 43 |
| Januvia | Sitagliptin Phosphate | 60 | 22 |
| Jardiance | Empagliflozin | 60 | 33 |
| Lovastatin | Lovastatin | 60 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 23 |
| Meclizine Hcl | Meclizine Hcl | 54 | 38 |
| Methylprednisolone | Methylprednisolone | 54 | 46 |
| Trazodone Hcl | Trazodone Hcl | 54 | 36 |
| Carvedilol | Carvedilol | 51 | 28 |
| Azelastine Hcl | Azelastine Hcl | 50 | 32 |
| Tramadol Hcl | Tramadol Hcl | 49 | 24 |
| Memantine Hcl | Memantine Hcl | 48 | 27 |
| Mirtazapine | Mirtazapine | 48 | 30 |
| Azithromycin | Azithromycin | 47 | 45 |
| Amoxicillin | Amoxicillin | 43 | 38 |
| Clobetasol Propionate | Clobetasol Propionate | 43 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 30 |
| Propranolol Hcl | Propranolol Hcl | 43 | 17 |
| Atenolol | Atenolol | 42 | 21 |
| Nifedipine Er | Nifedipine | 41 | 15 |
| Furosemide | Furosemide | 40 | 31 |
| Mupirocin | Mupirocin | 39 | 29 |
| Glipizide | Glipizide | 38 | 19 |
| Megestrol Acetate | Megestrol Acetate | 36 | 29 |
| Eliquis | Apixaban | 34 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 17 |
| Hydrocortisone | Hydrocortisone | 31 | 16 |
| Potassium Chloride | Potassium Chloride | 30 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | 13 |
| Ketoconazole | Ketoconazole | 27 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 23 |
| Telmisartan | Telmisartan | 27 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 27 | 14 |
| Valacyclovir | Valacyclovir Hcl | 27 | 15 |
| Metronidazole | Metronidazole | 26 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Celecoxib | Celecoxib | 25 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Ciclopirox | Ciclopirox | 21 | 11 |
| Colchicine | Colchicine | 21 | 14 |
| Baclofen | Baclofen | 20 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 19 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | 17 |
| Ondansetron Odt | Ondansetron | 17 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Linzess | Linaclotide | 15 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | 11 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | 12 |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $171.00 · 4 records | Gilead Sciences, Inc. | Cologuard Collection Kit, OTEZLA, REPATHA, Talicia, Vemlidy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vemlidy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error